|
Transdermal Delivery Platform
The Corporation's first technology platform is based on a transdermal carrier designed to
deliver drugs through the skin directly to the disease site. Unlike oral medications, Nuvo's
transdermal products do not rely on bloodstream circulation to reach affected parts of the body.
Drugs built on this platform offer site-specific treatment while limiting exposure to potentially
harmful levels of chemical agents.
Under the leadership of the new Board and management, there has been an increased focus on developing
an improved form of this drug delivery technology. The Corporation is currently developing a family
of improved skin penetration enhancers, with a number of formulations in the preclinical stage. The new
penetration enhancers are designed to expand the Corporation's drug carrier technology and to increase
safety and user compliance.
The Company is researching a number of different carriers and drug-carrier combinations through
fqubed Inc., our U.S. based research and development facility that has the capability to solve
skin delivery and anti-delivery problems by utilizing high-throughput experimentation systems that
screen different soft material formulations based on their affect on skin. These candidates represent
opportunities to change the method of administration for proven drugs from oral to topical.
Changing dosage form from oral to topical provides the possibly of reduced
dosage and fewer side effects. The transdermal expertise acquired through Pennsaid® development, positions the
company to create even safer and more effective topical products and it intends to
leverage its skin-penetrating technologies to create a portfolio of transdermal products targeting a variety
of indications.
|